BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17611656)

  • 1. Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes.
    Wu XX; Zeng Y; Jin XH; Kakehi Y
    Oncol Rep; 2007 Aug; 18(2):353-9. PubMed ID: 17611656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
    Mizutani Y; Yoshida O; Miki T
    J Urol; 1999 Dec; 162(6):2170-5. PubMed ID: 10569614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
    Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
    Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
    J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells, and effect of interferon-alpha and/or cimetidine on the expression].
    Wu XX; Mizutani Y; Kakehi Y; Nakamura E; Mitsumori K; Takahashi T; Terachi T; Okada Y; Yoshida O
    Hinyokika Kiyo; 1998 Sep; 44(9):621-6. PubMed ID: 9805665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
    Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
    J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
    Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis.
    Shabtai M; Ye H; Kono K; Takayam T; Terashima K; Tsukuda K; Frischer Z; Waltzer WC; Malinowski K
    Urol Oncol; 2003; 21(1):27-32. PubMed ID: 12684124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
    Mulders P; Tso CL; Pang S; Kaboo R; McBride WH; Hinkel A; Gitlitz B; Dannull J; Figlin R; Belldegrun A
    J Immunother; 1998 May; 21(3):170-80. PubMed ID: 9610908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal-cell carcinoma-specific lysis by cytotoxic T-lymphocyte clones isolated from peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Brouwenstijn N; Gaugler B; Krüse KM; van der Spek CW; Mulder A; Osanto S; van den Eynde BJ; Schrier PI
    Int J Cancer; 1996 Oct; 68(2):177-82. PubMed ID: 8900424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of lymphocyte adhesion to cultured human corneal epithelial cells.
    Iwata M; Sawada S; Sawa M; Thoft RA
    Curr Eye Res; 1997 Aug; 16(8):751-60. PubMed ID: 9255503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation.
    Wang YC; Zhu L; McHugh R; Graham SD; Hillyer CD; Dillehay D; Sell KW; Selvaraj P
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):1-8. PubMed ID: 9147700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
    Kowalczyk D; Skorupski W; Kwias Z; Nowak J
    Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
    Wang QJ; Hanada K; Robbins PF; Li YF; Yang JC
    Cancer Res; 2012 Dec; 72(23):6119-29. PubMed ID: 23071066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
    Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
    Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.